breast cancer
Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma
Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …
NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer
June 15, 2018Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma
Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …
Roche’s breast, lung cancer offerings fail to impress at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …
EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer
April 30, 2018Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …
Promising drug for hormone therapy-resistant breast cancer enters human trials
March 22, 2018Research and Development TTC-352, breast cancer, chicago, pharma
A team of researchers at Chicago’s University of Illinois (UIC) have revealed that their promising drug which could prove an …
FDA authorises first direct-to-consumer test for BRCA mutations, with caveats
March 6, 2018Research and Development, Sales and Marketing 23andME, BRCA, Cancer, FDA, breast cancer, ovarian cancer, pharma
The FDA has given its authorisation to the first ever direct-to-consumer (DTC) test to identify three BRCA gene mutations which …
Blood test could predict treatment effectiveness months earlier in breast cancer
March 6, 2018Manufacturing and Production, Research and Development Cancer, ICR, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, breast cancer, palbociclib, pharma
A team of scientists at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust have …
FDA expands indication of Lilly’s Verzenio in advanced breast cancer
February 27, 2018Manufacturing and Production, Sales and Marketing Cancer, Eli Lilly, FDA, Verzenio, breast cancer, pharma
Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval …
Abbott teams up with Angle for metastatic breast cancer study
February 6, 2018Manufacturing and Production, Research and Development Abbott, Angle, Cancer, breast cancer, pharma
Abbott is set to join forces with liquid biopsy medtech firm Angle to collaborate on a study into metastatic breast …
UK breast cancer mortality falls 10% over five years, overtaken by prostate deaths for first time
February 5, 2018Research and Development, Sales and Marketing Cancer, Cancer Research UK, breast cancer, pharma, prostate cancer
Breast cancer deaths in the UK have fallen by 10% in the past five years, according to research released by …
UK charity Breast Cancer Care receives £655,000 cash injection to expand end-of-treatment app
January 31, 2018Research and Development Breast Cancer Care, National lottery, UK, breast cancer, charity, pharma
UK charity Breast Cancer Care (BCC) is set to expand the development of its end-of-treatment support app after receiving a …
AZ and MSD’s Lynparza becomes first PARP inhibitor approved in US for metastatic breast cancer
January 15, 2018Sales and Marketing AstraZeneca, Cancer, FDA, MSD, breast cancer, lynparza, pharma
The FDA has announced that it has awarded marketing authorisation in the US to Lynparza (olaparib), a poly ADP-ribose polymerase …
FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy
December 21, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) …
University of Virginia researchers identify new target in triple-negative breast cancer
November 28, 2017Manufacturing and Production, Research and Development University of Virginia, breast cancer, pharma, triple-negative breast cancer
Researchers at the University of Virginia claim they have discovered a new target for triple-negative breast cancer, a notoriously aggressive …
NICE refuses Eisai’s breast cancer drug in new indication
November 28, 2017Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma
NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …
